In this episode, host Shikha Jain, MD, speaks with Ashley Sumrall, MD, about advocacy outside of their oncology practices and organizations, what lies ahead for the field of neuro-oncology and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Sumrall 1:16 •    The interview 2:54 •    How did you end up in the neuro-oncology space? 3:21 •    As a neuro-oncologist, how do you stay up-to-date with neurology, oncology and medicine? 7:28 •    Is there a difference in the way you interact with a neuro-oncologist versus a medical oncologist?  8:58 •    What drove you to get into the advocacy space? 10:09 •    Do you predominantly do advocacy work through ASCO, or do you do it through other avenues as well?  12:20 •    If someone is interested in getting involved in becoming an advocate with ASCO, on the local level or on the national level, what is the best way for them to start that process? 15:24 •    How do you talk to people in and outside of organizations about current situations facing health care? 19:40 •    If people are interested in learning more about the AMA or getting involved with an organization like the AMA, how can they do so? 22:31 •    What do you see coming down the pipeline that you think is going to transform the neuro-oncology space? 27:16 •    If someone could only listen to the last minute of this episode, what would you want them to take away? 30:04 •    How to contact Sumrall 32:13 •    Thanks for listening 32:56 Ashley L. Sumrall, MD, is a neuro-oncologist practicing at Levine Cancer Institute in Charlotte, NC.  We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Sumrall can be reached on X, formerly known as Twitter: @AshleySumrallMD.  Disclosures: Jain reports no relevant financial disclosures. Sumrall reports receiving funding from Bristol-Myers Squibb, Exelixis, Kura Oncology, Novocure and Oncoceutics, and being a consultant for Abbvie, Athenex, Bayer, Exelixis and Novocure. 

In this episode, host Shikha Jain, MD, speaks with George Sledge, MD, about patient feedback benefiting leadership decision-making, the future of precision medicine in oncology and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Sledge 1:03 •    The interview 2:59 •    How did you become an oncologist? 3:24 •    Tell us about your journey into leadership in oncology. 5:27 •    Did you continue to see patients while leading organizations?  7:48 •    Jain and Sledge on learning from conversations and experiences with patients. 10:57 •    How did you end up in your previous position as ASCO president?  12:29 •    Do you feel that ASCO is an organization that is adept at adapting to change? 14:37 •    Tell us about Caris Life Sciences and how you pivoted to your role as executive vice president and CMO there. 18:44 •    Where do you see the future of oncology going? 23:00 •    Jain and Sledge on the concerns surrounding artificial intelligence and technology in cancer care and the doctor patient relationship. 26:31 •    What is something aspirational that you think could change the way we deliver cancer care years from now? 31:11 •    If someone could only listen to the last minute of this episode, what would you want them to take away? 35:21 •    How to contact Sledge 36:37 •    Thanks for listening 37:10 George Sledge, MD, serves as executive vice president and chief medical officer at Caris Life Sciences. We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Sledge can be reached via email [email protected]. Disclosures: Jain reports no relevant financial disclosures. Sledge reports that he has stock options with Syndax.

In this episode, host Shikha Jain, MD, speaks with Jan Kitajewski, PhD, about blending community need with scientific advancement, his role as the director of a cancer care center and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Kitajewski 1:08 •    The interview 2:59 •    Tell me about how you started and your pathway to this position. 3:26 •    You have a very diverse background in various fields of medicine. Was there something that drew you to lead a cancer center? 6:15 •    What are your thoughts on how institutions can shift their mindsets toward setting up research that is more inclusive of patient diversity in clinical trials?  9:44 •    Jain and Kitajewski on The Immortal Life of Henrietta Lacks, mistrust in the health care system, and how institutions can empower their communities. 14:00 •    What does a cancer center director do, and what are some things that people may be surprised to know about your position?  16:30 •    Jain and Kitajewski on the University of Illinois Cancer Center applying for NCI designation, and what the process entails.  22:05 •    Jain and Kitajewski on the challenges and successes that come with physician leadership when making changes at an institution. 29:28 •    What is your vision for the future of the University of Illinois Cancer Center? 34:16 •    If someone could only listen to the last minute of this episode, what would you want them to take away? 40:13 •    How to contact Kitajewski 40:55 •    Thanks for listening 41:35 Jan Kitajewski, PhD, is director of the University of Illinois Cancer Center and a professor and head of the department of physiology and biophysics. We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Kitajewski can be reached via email [email protected]. Disclosures: Jain reports no relevant financial disclosures. Healio could not confirm relevant financial disclosures for Kitajewski at the time of posting.

In this episode, host Shikha Jain, MD, speaks with Avital O’Glasser, MD, about the challenges facing non-traditional scholarship, amplifying diverse voices in medicine and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About O’Glasser 1:15 •    The interview 2:36 •    Jain and O’Glasser on their friendship and how they met. 2:52 •    What is non-traditional scholarship, and why is it so difficult for academics to adopt to these practices? 5:16 •    Jain and O’Glasser on the added value of non-traditional scholarship in academia and engagement. 11:25 •    How can engaging in non-traditional scholarship be leveraged and disseminated along with more “traditionally” recognized ways of CME? 13:33 •    O’Glasser on Daniel Cabrera’s More Than Likes and Tweets: Creating Social Media Portfolios for Academic Promotion and Tenure and Ernest Boyer’s The Scholarship of Engagement. 17:19 •    Jain and O’Glasser on utilizing digital abstracts in presenting data and pushing back on non-promotable work.  18:30 •    How can physicians make sure that information reaches its desired audience through non-traditional scholarship, or provide more educational opportunities about this work?  22:29 •    About An Evolution of Empowerment: Voices of Women in Medicine and Their Allies, co-edited by Jain and O’Glasser, and their process in creating this publication. 24:28 •    Do you think we’ll collaborate on another book? 32:22 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 35:47 •    How to contact O’Glasser 36:45 •    Thanks for listening 38:08 Avital O’Glasser, MD, FACP, FHM, is a hospitalist and associate professor of medicine at Oregon Health & Science University.  Her clinical practice focus is perioperative medicine, and she is also the assistant program director for social media and scholarship for OHSU’s Internal Medicine Residency Program.   We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. O’Glasser can be reached on the Women In Medicine blog. Disclosures: Jain and O’Glasser report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with St. Jude’s Steven Gottschalk, MD, and Paulina Velasquez, MD, about the evolution of bone marrow transplant and cell therapy, increasing accessibility to CAR T-cell therapy and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Gottschalk 1:12 •    About Velasquez 1:57 •    The interview 2:23 •    About Gottschalk’s journey and how he ended up in this space. 2:56 •    About Velasquez’s journey and how she ended up in this space. 4:16 •    Gottschalk on the history of severe combined immune deficiency (SCID), or “bubble boy disease” and his work on developing the cure.  5:04 •    When you think about what we have learned about immunotherapy, immune systems and cancer treatment over the last fifty years, did you think we would be where we are today in cancer care? 7:27 •    How have CAR T-cells transformed health care so far, and what will they do for the future? 8:53 •    What are you currently working on, and what excites you most about that work?  9:57 •    Do you think that we can expect a transformation in CAR T-cells being used in solid tumors in the future? 12:34 •    How do we prioritize enhanced CAR T-cells in clinical studies? 13:38 •    How can we address the challenges facing the delivery of CAR T-cell therapy and make it more accessible to patients? 17:04 •    Where do you see CAR T-cell therapy going in cancer care and in immunodeficiencies? 21:03 •    If you were interviewed again in five years, what do you think you will be doing then, and what do you think we will be talking about? 25:42 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 30:31 •    How to contact Gottschalk and Velasquez 31:22 •    Thanks for listening 31:51 Stephen Gottschalk, MD, St. Jude Department of bone marrow transplantation and cellular therapy chair, focuses his research on cancer immunotherapy, cell therapy and stem cell transplantation. The Gottschalk laboratory focuses on Epstein-Barr virus-specific T cells for treating EBV-associated cancers and using genetically modified T cells for cancer immunotherapy.  Paulina Velasquez, MD, St. Jude Department of bone marrow transplantation and cellular therapy, has made significant contributions to the field of immunotherapy, developing novel T-cell therapy platforms for pediatric hematological malignancies. Her team is pursuing projects that address antigen discovery, tumor immune evasion, persistence and efficacy of CAR T cells and cell-cell interaction within the tumor microenvironment.  We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Gottschalk can be reached via email [email protected]. Velasquez can be reached via email [email protected].  Disclosures:  Jain reports no relevant financial disclosures. Gottschalk reports he is co-inventor on patents and patent applications in the fields of cell or gene therapy for cancer, a member of the scientific advisory board of Be Biopharma and CARGO, and the data and safety monitoring board (DSMB) of Immatics and has received honoraria from TESSA Therapeutics. Velasquez reports patent applications in the field of T-cell immunotherapy.

In this episode, host Shikha Jain, MD, speaks with Erica Barnell, MD, PhD, about Geneoscopy’s non-invasive screening and early detection technology, helping improve patient compliance for gastrointestinal health and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Barnell 1:07 •    The interview 2:05 •    Tell me about how you got into this space and co-founded your unique company. 2:30 •    How did you find the time to co-find a company on top of completing your PhD program? 4:24 •    Barnell on starting Geneoscopy with her brother and working with family. 5:06 •    What were the steps you took to make the idea of Geneoscopy happen? 6:08 •    Describe the process and technology Geneoscopy is using for early colorectal cancer screening. 7:33 •    What makes your non-invasive screening tests different from others?  9:29 •    Do you have any advice on how to execute a timeline for physicians and scientists who may have ideas like yours? 11:08 •    Jain and Barnell on the advantages of partnering with your network and connections to navigate the challenges of standing up entrepreneurial ventures. 13:36 •    How can physicians find resources outside of their network to help them successfully build a company and execute their ideas? 15:20 •    Tell me more about what Geneoscopy is looking at outside of cancer. 17:40 •    Is this technology something that patients can order directly, and are you thinking of expanding this globally in the future? 19:25 •    What do you envision for Geneoscopy ten years down the line? 20:37 •    Have you received feedback from other physicians? 21:39 •    Jain and Barnell on the positive results of patient compliance with non-invasive screening tests. 23:09 •    What’s next for you? Along with growing Geneoscopy, is there anything else that you are working on and passionate about? 24:54 •    Can you talk about how Geneoscopy has focused on equitable access in this space? 27:15 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 29:45 •    How to contact Barnell 30:20 •    Thanks for listening 31:02 Erica Barnell, MD, PhD, is the chief science officer and co-founder of Geneoscopy, a life sciences company focused on transforming gastrointestinal health by empowering patients and providers with innovative tests that help detect, prevent and monitor disease, including colorectal cancer. We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Barnell can be reached on X, formerly known as Twitter, @EricaBarnell, or via Geneoscopy’s LinkedIn and Facebook and website, geneoscopy.com.  Disclosures:  Jain reports no relevant financial disclosures. Barnell is the CSO and cofounder of Geneoscopy.

In this episode, host Shikha Jain, MD, speaks with Laura Petrillo, MD, about navigating patients through changes and goals in palliative care, understanding patients living with and surviving advanced cancer and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Petrillo 1:03 •    The interview 1:40 •    How did you find yourself in medicine, specifically in palliative care and geriatrics? 2:04 •    How has the evolution of cancer care and technology impacted the way you engage and deliver palliative care? 6:46 •    Jain and Petrillo on the effect changes in palliative care can have on patients. 12:47  •    How do you communicate the distinctions between palliative care and hospice care to patients and physicians? 17:19 •    Do you think that there are ways for people outside of palliative care can incorporate intentional communication with patients in their care? … When should you refer someone to palliative care? 23:45 •    Petrillo and Jain on advanced cancer survivorship and living with advanced cancer.  30:54 •    Jain and Reynolds on the progress made in this space and the road ahead. 29:43 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 36:41 •    How to contact Petrillo 38:30 •    Thanks for listening 38:58 Laura Petrillo, MD, is a palliative care physician-investigator in the Division of Palliative Care and Geriatrics at MGH and an assistant professor of medicine at Harvard Medical School. We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Petrillo can be reached on X, formerly known as Twitter, @lpetrillz.  Disclosures:  Jain and Petrillo report no relevant financial disclosures.

In this episode, host Shikha Jain, MD, speaks with Kerry Reynolds, MD, about immunotherapy-related adverse events, creating educational resources on immunotherapy management and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Reynolds 1:06 •    The interview 2:45 •    Tell me about how your journey led you to this field of immunotherapy-related adverse events? 3:12 •    Jain and Reynolds on how immunotherapy has changed how we talk about cancer care. 5:41 •    How did you start the Severe Immunotherapy Complications Service? 6:16 •    When you envision this program, what do you feel are the short-term and long-term goals?  10:47  •    Can you tell me more about how you care for and manage in-patients through your program? 14:34 •    As we learn more, do you think there will ever be a day where all immunotherapy side effects will be able to be managed in the outpatient setting? 16:34 •    How do people get into this clinic, and what types of patients are admitted? 18:35 •    Tell me about your book, Facing Immunotherapy: A Guide for Patients and Their Families. Who is the best audience for this book? 21:35 •    Along with this book, are there other educational resources or initiatives that raise awareness for management of severe immunotherapy complications? 24:56 •    Have you encountered any challenges or obstacles while creating and maintaining educational resources and research initiatives?  27:11 •    Jain and Reynolds on the progress made in this space and the road ahead. 29:43 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 31:10 •    How to contact Reynolds 32:40 •    Thanks for listening 33:27 Kerry Reynolds, MD, is an oncologist at the Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard Medical School. We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Reynolds can be reached at MGH SIC, or via email  [email protected]. Disclosures:  Jain reports no relevant financial disclosures. Reynolds reports BMS Institutional research support and is on the advisory board for SAGA Diagnostics.

In this episode, host Shikha Jain, MD, speaks with Amy Comander, MD, about incorporating lifestyle changes for cancer patients, developing lifestyle pathways for survivors and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Comander 1:14 •    The interview 3:40 •    How do you manage to incorporate running on such a high level into your day-to-day life? 4:04 •    Tell us about what lifestyle medicine is and why it is so important to include in patient care? 6:43 •    How do you suggest oncologists who are interested in integrating lifestyle medicine into their treatment plans communicate these changes to their patients? 10:06 •    Jain and Comander on the importance of physical activity in cancer care.  12:09  •    Do you have standard recommendations you give to patients to begin incorporating physical activity and exercise to their treatment plan? 13:34 •    About Comander’s patient, and her Walk with Me movement. 16:13 •    How do you incorporate lifestyle health into survivorship discussions after treatment? 17:12 •    Jain and Comander on the evolution of medicine allowing there to be more metrics for holistic care and empowerment for patients. 19:02 •    What types of clinical trials are there for lifestyle medicine? 21:19 •    Comander on The Diet, Exercise, Lifestyles, and Cancer Prognosis Study (DELCaP).  21:45 •    How do you talk to people who may not understand lifestyle medicine or its impact? 23:33 •    Can you talk about the PAVING the Path to Wellness program? 24:54 •    What is the training process for physicians looking to become a lifestyle medicine specialist? 28:40 •    Is there an optimal way to incorporate these specialists in patients’ day-to-day without it being a burden for them? 31:11 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 33:13 •    How to contact Comander 34:26 •    Thanks for listening 35:37 Amy Comander, MD, is a breast oncologist at the Massachusetts General Hospital Cancer Center. We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Comander can be reached on via the MGH Cancer Center website, on Instagram and Threads @dramycomander or on X, formerly known as Twitter @DrAmyComander. Disclosures:  Jain and Comander report no relevant financial disclosures.

In this episode, host Shikha Jain, MD, speaks with Pia Chowdry, MD, about access to care in rural communities, how physicians can present information to patients and their caregivers and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Chowdry 1:04 •    The interview 1:54 •    What was your journey into oncology and how did you end up practicing in Louisiana? 2:07 •    Can you talk about your work in racial and ethnic disparities, variables in cancer care, and prevention? 4:18 •    Do you feel like being exposed to rural health care settings and challenges has changed the way you practice and talk about care to people outside the area? 6:19 •    How do you navigate enrolling patients in rural areas into clinical trials?  10:35  •    Jain and Chowdry on misconceptions surrounding clinical trial enrollment in rural areas. 12:42 •    What excites you about your job and motivates you to avoid burnout? 13:48 •    Has your experience as a caregiver for patients with cancer affected the ways in which you navigate patients and caregivers through treatment and care? 16:25 •    Jain and Chowdry on the importance of how physicians present themselves to patients and caregivers. 19:39 •    Chowdry and Jain on obstacles facing cancer care in rural areas, as well as benefits. 24:25 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 30:41 •    How to contact Chowdry 31:54 •    Thanks for listening 32:28 Pia Chowdry, MD, is a medical oncologist with LSU Health in New Orleans, LA specializing in genitourinary malignancies. We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Chowdry can be reached on X, formerly known as Twitter @Pia_Chowdry, or via email [email protected]. Disclosures:  Jain and Chowdry report no relevant financial disclosures.